NASDAQ · TRIB
Trinity Biotech plc
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
Loading market information…
NASDAQ · TNON · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tenon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Tenon Medical, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$4.23. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tenon Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$35.31-1.9% vs estimate | $726.00K-6.68% vs estimate |
|---|
| Q4 2024 | Mar 20, 2025 | -$3.69-179.31% vs estimate | $800.00K-11.21% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$1.27+14.39% vs estimate | $887.00K-29.6% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $2.25.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.29+$0.03 (+11.36%)
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.72% below the high.
$1.22-$0.02 (-1.61%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
$1.72-$0.02 (-1.15%)
Sintx Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.43% below the high.
$5.91+$0.16 (+2.78%)
Lifeward Ltd.’s quoted price sits in the lower half of its reported 52-week range, 38.5% below the high.
$5.52-$0.03 (-0.54%)
Aethlon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.6% below the high.
$2.31-$0.05 (-2.12%)
Beyond Air, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.66% below the high.
